Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
These approvals will incite a modest reorganisation in the market of antibody-based therapies for the illness.
Immuno
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
Asbestos-related cancers still prevalent in the UK
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
Implementing pragmatic approaches for the patients and sites in oncology trials
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
